Electronic Identification and Trust Services for Electronic... · SCHEDULE 3

9 National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

Sch. 3 para. 9 · in force: yes

Captured statutory text (L5)

9 National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013

In regulation 2(1) (interpretation) of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 —

(a)for the definition of “advanced electronic signature”, substitute— “advanced electronic signature” means an electronic signature which meets the following requirements—

(a)it is uniquely linked to the signatory;

(b)it is capable of identifying the signatory;

(c)it is created using electronic signature creation data that the signatory can, with a high level of confidence, use under the signatory's sole control; and

(d)it is linked to the data signed in such a way that any subsequent change in the data is detectable;

;

(b)after the definition “electronic repeatable prescription”, insert— “electronic signature” means data in electronic form which is attached to or logically associated with other data in electronic form and which is used by the signatory to sign; “electronic signature creation data” means unique data which is used by the signatory to create an electronic signature; ; and

(c)after the definition “scheme premises” insert— “signatory” means a natural person who creates an electronic signature; .

Full captured verbatim text

In regulation 2(1) (interpretation) of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 —

(a) for the definition of “advanced electronic signature”, substitute—

“advanced electronic signature” means an electronic signature which meets the following requirements—

(a) it is uniquely linked to the signatory;

(b) it is capable of identifying the signatory;

(c) it is created using electronic signature creation data that the signatory can, with a high level of confidence, use under the signatory's sole control; and

(d) it is linked to the data signed in such a way that any subsequent change in the data is detectable;

;

(b) after the definition “electronic repeatable prescription”, insert—

“electronic signature” means data in electronic form which is attached to or logically associated with other data in electronic form and which is used by the signatory to sign;

“electronic signature creation data” means unique data which is used by the signatory to create an electronic signature;

; and

(c) after the definition “scheme premises” insert—

“signatory” means a natural person who creates an electronic signature;

.

What this provision means

Model summary, checked against the text on the left.

Relevance to Signicat: 2/3 · detailed summary (L4) Status: not needed for a short provision · Stored artifact; current recipe verification unavailable

The NHS pharmaceutical services regulations are amended with detailed technical criteria for advanced electronic signature and related definitions.

Only the one-line summary above is stored for this provision; the text itself is the evidence.

Refers to

No captured references.

Referred to by

schedule ref schedule_ref · reg. 5

Part summaries

0 of 0 parts have a verified summary.

L1 unavailable for current verification: the overall summary needs every part verified. Provisions and the verified summaries remain readable.

Verification findings (75)

synthesis coverage: missing/unverified L2 part-1

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-1

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-2

synthesis coverage: missing/unverified L2 part-2

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-3

synthesis coverage: missing/unverified L2 part-3

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-4

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-5

synthesis coverage: missing evaluation uk:uksi/2016/696#regulation-6

synthesis coverage: missing/unverified L2 schedule-1

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-1-paragraph-11

synthesis coverage: missing/unverified L2 schedule-2

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-6A

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-7A

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-7B

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-19

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-20

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-21

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-22

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-23

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-24

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-25

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-26

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-2-paragraph-27

synthesis coverage: missing/unverified L2 schedule-3

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-19

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-20

synthesis coverage: missing evaluation uk:uksi/2016/696#schedule-3-paragraph-21

Instrument tier unavailable

Change history as published

Sch. 3 para. 7 revoked (24.2.2025) by The Procurement Act 2023 (Consequential and Other Amendments) Regulations 2025 (S.I. 2025/163), reg. 1(2), Sch. Pt. 2

Sch. 3 para. 17 revoked (24.2.2025) by The Procurement Act 2023 (Consequential and Other Amendments) Regulations 2025 (S.I. 2025/163), reg. 1(2), Sch. Pt. 2

Sch. 3 para. 20 revoked (24.2.2025) by The Procurement Act 2023 (Consequential and Other Amendments) Regulations 2025 (S.I. 2025/163), reg. 1(2), Sch. Pt. 2

Pending effects amendments not yet applied to this text

No captured pending effects.

Provenance

Every claim the system makes about this text is traceable to these identifiers.

Instrument: uk:uksi/2016/696
Part: SCHEDULE 3
Version: d49dbc556a03966e92c4becd…
Content hash: sha256 17ffb07717f155b4949e1692…
Source: legislation.gov.uk/uksi/2016/696